target/Antiviral/1

Target 1 has a wide range of applications in life science related research.

Olgotrelvir is an antiviral agent [1]. It inhibits viral replication by targeting key viral enzymes, thereby reducing the viral load in infected cells. The compound exhibits specificity for its target enzymes, which minimizes off-target effects and enhances its therapeutic profile. Clinical studies demonstrate its efficacy against a range of viral pathogens.

Compound 23, also known as PAN endonuclease-IN-1, demonstrates potent inhibitory activity against PAN endonuclease, a vital element of the influenza virus replication machinery and a significant antiviral target [1]. It exhibits dissociation constants (Kd) of 277 μM, 384 μM, and 328 μM for the wild type (WT), I38T, and E23K variants of PAN endonuclease respectively.

SARS-CoV-2 3CLpro-IN-1 (Compound 14c) is a highly potent inhibitor specifically designed to target and inhibit the activity of SARS-CoV-2 3CL pro, a cysteine protease found in the main coronaviruses. This enzyme is a promising target for antiviral drug development, positioning SARS-CoV-2 3CLpro-IN-1 as significant for advancing research in infectious diseases [1].

Interferon alfa, a type I interferon, activates new genes, displaying strong antiviral and antiproliferative effects on target cells. It signals through receptor-mediated activation of Stat1 and Stat2, which heterodimerize into a STAT complex binding with the DNA-binding protein IRF-9 (p48) to form ISGF-3 (IFN-stimulated gene factor 3). This complex further activates driver genes to fulfill its antiviral role [1].

DDX3-IN-2, a potent inhibitor of DEADbox polypeptide 3 (DDX3), demonstrates remarkable activity against the target with an IC50 value of 0.3 μM. Notably, this compound exhibits a wide range of antiviral effects, showcasing its efficacy against various viral strains. Importantly, DDX3-IN-2 exhibits the potential to overcome resistance observed in the context of HIV [1].